Abstract:Potential conflict of interest: Nothing to report. This work is supported by the National Natural Science Foundation of China (grant 81902379) and the Cultivation Foundation of Renji Hospital (grant PY2018‐III‐01). To the Editor: We read with great interest the recent article by De Martin et al.(1) regarding the analysis of liver transplantation (LT) versus liver resection (LR) for patients with cirrhosis with small intrahepatic cholangiocarcinoma (iCCA) and combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA). The authors retrospectively evaluated a total of 75 patients with cirrhosis who were confirmed iCCA/cHCC‐CCA ≤5 cm and compared them by different operation types of LT or LR. Surprisingly, 49 LT patients had a significantly better 5‐year recurrence‐free survival compared with patients in the LR group (75% versus 36%; P = 0.004). The overall survival was also comparable between 2 groups. The results are encouraging for patients suffering iCCA/cHCC‐CCA with limited therapies, and the findings may suggest an expansion of the criteria of LT. The authors also analyzed a subgroup of patients with tumors >2 cm but <5 cm. Consistent with previous results, a favorable outcome was also confirmed in LT patients with a 5‐year recurrence‐free survival of 74%. In addition, tumor differentiation was found to be independently associated with tumor recurrence. On the basis of these findings, the authors concluded that LT could provide a better strategy for patients with cirrhosis with iCCA/cHCC‐CCA <5 cm. We appreciate the well‐designed research that evaluates LT for cholangiocarcinoma. However, certain points need to be further discussed when interpreting the results. First of all, transarterial chemoembolization (TACE) for liver tumors has been acknowledged as one of the locoregional treatments that inhibits active tumor cells, induces tumor necrosis, and reduces vascular metastasis.(2) However, a significantly higher rate of preoperative TACE treatment was found in the LT group (P = 0.005). This may provide potential benefits for LT patients in evaluating posttransplant outcomes. Second, there is increasing evidence showing that the biological stability of a tumor appears to be more important for prognosis than tumor size and number. Lunsford et al.(3) reported that patients with iCCA who showed tumor stability on preoperative neoadjuvant therapy benefited from LT. In the present study, a longer interval was revealed between tumor diagnosis and operation in patients receiving LT. However, neither tumor growth nor falling outside the French alpha‐fetoprotein criteria was reported in these patients, who demonstrated tumor stability rather than tumor category as defined only by tumor size. This subgroup of patients should be further evaluated in detail. Another important issue is related to lymph node status, which is an important factor impacting patient survival after operation for cholangiocarcinoma.(4) The absence of lymph node metastasis has been listed as one of the standards for LT in hilar cholangiocarcinoma.(5) However, because of a lack of diagnosis of iCCA/cHCC‐CCA before transplant, the authors did not routinely perform lymphadenectomy in the present study. Therefore, future studies should include lymph node dissection during LT to confirm whether positive nodes affect the prognosis in LT for small iCCA/cHCC‐CCA. In conclusion, the recommendation of LT for patients with cirrhosis with iCCA/cHCC‐CCA <5 cm needs further exploration in larger, prospective studies with careful evaluation in tumor biological stability and lymph node status. We believe that in selected patients with iCCA/cHCC‐CCA, LT could provide a favorable prognosis.

Liver transplantation for critically Ill patients with secondary sclerosing cholangitis: Outcome and complications

Outcome of patients with ischemic-like cholangiopathy with secondary sclerosing cholangitis after liver transplantation

Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: A systematic review.

Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis

Liver transplant in patients with primary sclerosing cholangitis: A retrospective cohort from Northeastern Brazil

COVID-19-associated secondary sclerosing cholangitis with liver transplantation

Biliary Cast Syndrome and Secondary Sclerosing Cholangitis in Critically Ill Patient after Long-Term Treatment in the Intensive Care Unit

Sclerosing Cholangitis in Critically Ill Patients: an Important and Easily Ignored Problem Based on a German Experience

The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience.

Trends in liver transplantation for primary sclerosing cholangitis

Severe sclerosing cholangitis after Langerhans cell histiocytosis treated by liver transplantation: An adult case report.

Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study

Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis

Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement

Post-COVID-19 Secondary Sclerosing Cholangitis: A Rare but Severe Condition with no Treatment Besides Liver Transplantation

Liver Transplantation in Acute-on-chronic Liver Failure Patients with High Model for End-Stage Liver Disease (MELD) Scores: a Single Center Experience of 100 Consecutive Cases.

Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation.

Hepatobiliary long-term consequences of COVID-19: dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients

The Morbidity and Survival of 196 Consecutive Cases Undergoing Liver Transplantation in a Single Center in Mainland China: Ten-Year Experience.

Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular‐Cholangiocarcinoma in the Setting of Cirrhosis

Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma Within UCSF Criteria after Liver Resection